


Chrexanthomycin C

Cat. No.:	HY-N10579
Molecular Formula:	C ₃₁ H ₂₄ O ₁₅
Molecular Weight:	636.51
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Chrexanthomycin C is an orally active marine natural product with remarkable bioactivities. Chrexanthomycin C has binding affinity for DNA (G4C2) ⁴ G4 with a K _d value of 2.8 mM. Chrexanthomycin C can be used for the research of neurodegenerative disease such as amyotrophic lateral sclerosis (ALS) ^[1] .								
IC₅₀ & Target	Kd: 2.8 mM (DNA (G4C2) ⁴ G4) ^[1]								
In Vitro	<p>Chrexanthomycin C (Compounds cC) (0.1-10 mM) binds DNA (G4C2)⁴ G4 with a K_d value of 2.8 mM^[1]. Chrexanthomycin C has good permeability, low cytotoxicity, and nonhemolytic activity^[1]. Chrexanthomycin C (1.57 μM) rescues G4C2 EHR-related pathologies in cells^[1]. Chrexanthomycin C selectively binds to DNA and RNA G4C2 G4s^[1]. Chrexanthomycin C (0-100 μM) dramatically reduces G4C2 EHR-caused cell death, diminish G4C2 RNA foci in (G4C2)²⁹-expressing Neuro2a cells, and significantly eliminate ROS in HT22 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HEK293T cells</td> </tr> <tr> <td>Concentration:</td> <td>0.16, 1.57 and 15.67 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed no cytotoxicity up to the concentration of 10 μg/mL.</td> </tr> </table>	Cell Line:	HEK293T cells	Concentration:	0.16, 1.57 and 15.67 μM	Incubation Time:	24 h	Result:	Showed no cytotoxicity up to the concentration of 10 μg/mL.
Cell Line:	HEK293T cells								
Concentration:	0.16, 1.57 and 15.67 μM								
Incubation Time:	24 h								
Result:	Showed no cytotoxicity up to the concentration of 10 μg/mL.								
In Vivo	<p>Chrexanthomycin C (Compounds cC) (fed; 100 μM) significantly rescues eye degeneration and improve locomotor deficits in (G4C2)²⁹-expressing^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Drosophila^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 μM</td> </tr> <tr> <td>Administration:</td> <td>fed</td> </tr> </table>	Animal Model:	Drosophila ^[1]	Dosage:	100 μM	Administration:	fed		
Animal Model:	Drosophila ^[1]								
Dosage:	100 μM								
Administration:	fed								

Result:	Rescued G4C2 EHR-Related Pathologies in Drosophila.
---------	---

REFERENCES

[1]. Aifang Cheng, et al. Selective C9orf72 G-Quadruplex-Binding Small Molecules Ameliorate Pathological Signatures of ALS/FTD Models. Journal of Medicinal Chemistry Article ASAP.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA